Document 6594222

NEWS
th
00th
2014 2014
10 MONTH
Novemeber
Last week saw markets edge slightly higher, with European indices up ~0.5% on the week. We saw potential for markets
to gain a further 1-3% before meeting new resistance. As such, we continue to see the possibility for a small move higher
this week, though we remain selective with our stock picks. Modestly better earnings and dovish comments from Central
Banks have buoyed markets. However, we note that the rally since mid Oct has been on far weaker volume than the
selloff seen at the start of the quarter, suggesting a lack of conviction on the part of investors. This week will see some
key economic data, with Chinese PPI and CPI Monday, Bank of England Inflationary report on Wednesday, Chinese
Retail Sales & Industrial Production, German CPI and ECB Monthly report on Thursday, and the week concludes with
German GDP, Eurozone CPI, US Retail Sales and University of Michigan Business Confidence on Friday.
Equities Commentary
This week’s market events
Big Oil – Exxon Mobil and Royal Dutch Shell our preferred names
M
Despite the falling oil price, our two „Big Oil‟ plays from the core portfolio reported strong
earnings last week, and we reiterate our positive stance on these names. Royal Dutch
Shell (N/C) reported Q3 EPS of $0.923, ahead of consensus estimates of $0.875 as the
company continued its focus on high margin production and divestments from non-core
assets. The shares are trading on a FY15 EV/EBITDA of 4.2x, a discount to peers on 4.7x,
while offering an attractive FY15 dividend yield of 5.6%. Similarly, Exxon Mobil (N/C) also
beat market expectations, with EPS of $1.89 against consensus of $1.71. Strong
performance in the downstream division offset the impact of lower upstream realisations.
The shares are trading on FY15 EV/EBITDA of 6.4x with a dividend yield of ~3%.
T
W
T
Construction sector – Earnings this week
CRH (HOLD – TP GBp1500) is to release an IMS tomorrow. In our view, any progress on
asset sales should see a corresponding positive response in the share price. Our target
price of GBp1500 implies a 6.7% upside. Grafton Group (N/C) will release its IMS on
Thursday. The company‟s half year results in August highlighted the significant
improvement in fortunes at Grafton, as Profit Before Tax increased 88% YoY. We remain
very positive on its business model, and management‟s abilities. We would note however
the significant rally in the shares in recent weeks, resulting in an expensive FY14 PE of
20.4x. That said, this valuation falls to 13.6x on 2016 earnings, reflective of the significant
growth potential in the company. In addition this morning, Kingspan‟s (N/C) IMS showed a
5% YoY increase in revenue YTD, and noted the historical seasonal strength of Q4.
Vodafone (N/C) – H1/15 earnings on tap tomorrow
Ahead of H1 earnings tomorrow, we remain positive on the core portfolio stock. The
company is investing heavily in both its network and retail space, and is seeking to expand
in emerging markets as competition in Europe remains high. While there is scope for
beneficial M&A within Europe, Africa is becoming increasingly important. For example,
customers of the company‟s South African business, Vodacom (65% owned by Vodafone),
spent more time on the phone last year than the entire German market, Vodafone‟s largest
geography by sales. Vodafone is going through a transition since the sale of its Verizon
stake, and as such, 2015 earnings estimates have declined accordingly. However, we
believe there remains significant value in the shares, especially in light of the 5.45%
expected dividend yield for 2015.
Equities
Portfolio Management
Research
ECONOMICS
CH - PPI YoY
CH – CPI YoY
CH – New Yuan
Loans
Irish Recovery Story – Meeting with the NTMA, AIB and BOI
We held an institutional investor day at our Dublin offices last Friday, focusing on the Irish
economic recovery. Speakers included AIB CFO, Mark Bourke, Chief Economist from the
NTMA Rossa White, and Andrew Keating, CFO of Bank of Ireland. In our view, Bank of
Ireland (BUY, TP €0.35) continues its steady recovery, growing its loan book and improving
its capital generation. Despite a return to profit, AIB (SELL, TP €0.025) remains a
conviction sell, given the likely upcoming capital reorganisation. We expect this pricing
anomaly to be resolved in 2015 with both the Government and management noting the
elevated nature of the valuation. The NTMA completed a successful year of funding last
week, selling €3.75bn worth of 15 year bonds at a yield of 2.4%.
CORPORATE
AIB - IMS
Kingspan - IMS
F
CORPORATE
Vodafone – H1/15
CRH - IMS
Lufthansa – Traffic
Stats
ECONOMICS
GE – Wholesale
Price Index YoY
CORPORATE
ECONOMICS
Tullow Oil - IMS EZ – Industrial Prod
YoY
Barratt
Developments - UK – BoE Inflation
IMS
Report
E.ON – IMS
Burberry – IMS
Air France KLM –
Traffic Stats
Cisco – Q1/15
J Sainsbury - IMS
ECONOMICS
CORPORATE
Grafton Group - IMS CH – Retail Sales
YoY
UTV – IMS
Rolls Royce - IMS CH – Indust. Prod.
YoY
SAB Miller – H1/14
GE – CPI YoY
Premier Oil – IMS
FR – CPI YoY
Rexam - IMS
ECB Monthly
Report
CORPORATE
n/a
ECONOMICS
GE – GDP YoY
EZ – CPI YoY
US – Retail Sales Ex
Auto YoY
US – Univ. Mich.
Confidence
US – Business
Inventories
Upcoming Events
17/11/2014
18/11/2014
18/11/2014
18/11/2014
18/11/2014
18/11/2014
ICG - IMS
Prudential - IMS
Paddy Power - IMS
FBD - IMS
Hibernia REIT - IMS
easyJet – FY14
Bonds
Regulatory Information
This material is approved for distribution in Ireland by Cantor Fitzgerald Ireland Ltd. Cantor Fitzgerald Ireland Ltd (“CFIL”) is regulated by the Central
Bank of Ireland. Cantor Fitzgerald Ireland Ltd is a member firm of the Irish Stock Exchange and the London Stock Exchange.
Where CFIL wishes to make this and other Cantor Fitzgerald research available to Retail clients, such information is provided without liability and in
accordance with our terms and conditions that are available on the CFIL website.
No report is intended to and does not constitute a personal recommendations or investment advice nor does it provide the sole basis for any
evaluation of the securities that may be the subject matter of the report. Specifically, the information contained in this report should not be taken as
an offer or solicitation of investment advice, or to encourage the purchased or sale of any particular security. Not all recommendations are
necessarily suitable for all investors and CFIL recommend that specific advice should always be sought prior to investment, based on the particular
circumstances of the investor either from your CFIL investment adviser or another investment adviser.
CFIL takes all responsibility to ensure that reasonable efforts are made to present accurate information but CFIL gives no warranty or guarantee as
to, and do not accept responsibility for, the correctness, completeness, timeliness or accuracy of the information provided or its transmission. This is
entirely at the risk of the recipient of the report. Nor shall CFIL, its subsidiaries, affiliates or parent company or any of their employees, directors or
agents, be liable to for any losses, damages, costs, claims, demands or expenses of any kind whatsoever, whether direct or indirect, suffered or
incurred in consequence of any use of, or reliance upon, the information. Any person acting on the information contained in this report does so
entirely at his or her own risk
All estimates, views and opinions included in this research note constitute CANTOR IRELAND‟s judgment as of the date of the note but may be
subject to change without notice. Changes to assumptions may have a material impact on any recommendations made herein.
Unless specifically indicated to the contrary this research note has not been disclosed to the covered issuer(s) in advance of publication.
Past performance is not a reliable guide to future performance. The value of your investment may go down as well as up. Investments denominated
in foreign currencies are subject to fluctuations in exchange rates, which may have an adverse affect on the value of the investments, sale proceeds,
and on dividend or interest income. The income you get from your investment may go down as well as up. Figures quoted are estimates only; they
are not a reliable guide to the future performance of this investment.
Conflicts of Interest & Share Ownership Policy
It is noted that research analysts' compensation is impacted upon by overall firm profitability and accordingly may be affected to some extent by
revenues arising other CANTOR IRELAND business units including Fund Management and Stock broking. Revenues in these business units may
derive in part from the recommendations or views in this report. Notwithstanding, CANTOR IRELAND is satisfied that the objectivity of views and
recommendations contained in this note has not been compromised. Nonetheless CANTOR IRELAND is satisfied that the impartiality of research,
views and recommendations remains assured.
Our conflicts of interest management policy is available at the following link;
http://www.cantorfitzgerald.ie/regulation_mifld.shtml
Analyst Certification
Each research analyst responsible for the content of this research note, in whole or in part, certifies that: (1) all of the views expressed accurately
reflect his or her personal views about those securities or issuers; and (2) no part of his or her compensation was, is, or will be, directly or indirectly,
related to the specific recommendations or views expressed by that research analyst in the research note.
US distribution
This research note is being distributed by (CF Ireland / CF Europe / CF US / CF Canada / CF Hong Kong) in the United States and is intended for
distribution in the United States solely to “major U.S. institutional investors” (as such term is defined in Rule15a-6 of the U.S. Securities Exchange
Act of 1934 and applicable interpretations relating thereto) and is not intended for the use of any person or entity that is not a major institutional
investor. This material is intended solely for institutional investors and investors who Cantor reasonably believes are institutional investors. It is
prohibited for distribution to non-institutional clients including retail clients, private clients and individual investors. Major Institutional Investors
receiving this research note should effect transactions in securities discussed in this research note through Cantor Fitzgerald & Co. This research
note has been prepared in whole or in part by research analysts employed by non-US affiliates of Cantor Fitzgerald & Co that are not registered as
broker-dealers in the United States. These non-US research analysts are not registered as associated persons of Cantor Fitzgerald & Co. and are
not licensed or qualified as research analysts with FINRA or any other US regulatory authority and, accordingly, may not be subject (among other
things) to FINRA‟s restrictions regarding communications by a research analyst with a subject company, public appearances by research analysts,
and trading securities held by a research analyst account.
UK distribution
This research note is approved for distribution in the United Kingdom by Cantor Fitzgerald Europe (“CFE”). CFE is authorised and regulated by the
Financial Conduct Authority (“FCA”). While we believe this information and the materials upon which this information was based is accurate, except
for any obligations under the rules of the FCA, we do not guarantee its accuracy. This material is only intended for use by eligible counterparties or
professional clients who fall within articles 19 or 49 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2001 and not the
general investing public. None of the investments or investment services mentioned or described herein are available to other persons in the U.K
and in particular are not available to "retail clients” as defined by the rules of the FCA.
Other important disclosures
Prices quoted in this research note, unless otherwise indicated, are as of close on the previous trading day.
The distribution of this research note in other jurisdictions may be restricted by law and persons into whose possession this specialist sales market
commentary publication comes should inform themselves about and observe any such restrictions. By accepting this research note you agree to be
bound by the foregoing instructions.
Sources: CANTOR IRELAND Research, Bloomberg
Dublin: 75 St. Stephen‟s Green, Dublin 2, Ireland. Tel : +353 1 633 3800. Fax : +353 1 633 3856/+353 1 633 3857
CORK: Dolmen House, 45 South Mall, Cork. Tel: +353 21 422 2122.
LIMERICK: Theatre Court, Lower Mallow Street, Limerick. Tel: +353 61 436500.
Email : ireland@cantor.com web : www.cantorfitzgerald.ie
Equities
Portfolio Management
Research
Bonds